SELLAS Life Sciences Group, Inc. announced the appointment of Andrew Elnatan as Vice President, Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls (CMC) and Quality. He joins the Companys executive leadership team and is responsible for developing and executing regulatory strategies. Elnatan has extensive regulatory and CMC pharmaceutical industry experience in the areas of oncology, immunology, and hematological diseases.

His career spans over 25 years at companies such as Amgen, SQZ Biotechnologies Company, International AIDS Vaccine Initiative, and Celldex Therapeutics. He has successfully coordinated regulatory submissions, negotiations and approvals of drugs and biologics with several global regulatory bodies, including the US Food and Drug Administration (FDA), Chinas National Medical Products Administration Center for Drug Evaluation, Taiwan Food and Drug Administration, Australian Therapeutic Goods Administration, and the European Medicines Agency and other EU national agencies. This includes achievement of US FDA Breakthrough Therapy Designation granted for an oncology asset.